Publications by authors named "Bilal Mateen"

Article Synopsis
  • There is a significant risk of reinforcing existing health inequalities in AI health technologies due to biases, primarily stemming from the datasets used.
  • The STANDING Together recommendations focus on transparency in health datasets and proactive evaluation of their impacts on different population groups, informed by a comprehensive research process with over 350 global contributors.
  • The 29 recommendations are divided into guidance for documenting health datasets and strategies for using them, aiming to identify and reduce algorithmic biases while promoting awareness of the inherent limitations in all datasets.
View Article and Find Full Text PDF
Article Synopsis
  • This review analyzes various mammography datasets used for AI development in breast cancer screening, focusing on their transparency, content, and accessibility.
  • A search identified 254 datasets, with only 28 being accessible; most datasets came from Europe, East Asia, and North America, raising concerns over poor demographic representation.
  • The findings highlight significant gaps in diversity within these datasets, underscoring the need for better documentation and inclusivity to enhance the effectiveness of AI technologies in breast cancer research.
View Article and Find Full Text PDF
Article Synopsis
  • During the COVID-19 pandemic, AI models were developed to help with health-care resource issues, but previous studies showed that the datasets used often have limitations leading to biased outcomes.
  • A systematic review analyzed 192 healthcare datasets from MEDLINE and Google Dataset Search, focusing on metadata completeness, accessibility, and ethical considerations.
  • Results indicated significant shortfalls, including that only 48% showed the country of origin, 43% reported age, and under 25% included demographic factors like sex or race, emphasizing the need for improved data quality and transparency to avoid bias in future AI health applications.
View Article and Find Full Text PDF

Emergency admissions (EA), where a patient requires urgent in-hospital care, are a major challenge for healthcare systems. The development of risk prediction models can partly alleviate this problem by supporting primary care interventions and public health planning. Here, we introduce SPARRAv4, a predictive score for EA risk that will be deployed nationwide in Scotland.

View Article and Find Full Text PDF

Objective: To investigate the changing characteristics of SARS-CoV-2-related pediatric hospital admissions over time.

Study Design: This was a national, observational cohort study from July 1, 2020, to August 31, 2023, using English population-linked electronic health records. We identified 45 203 children younger than 18 years old in whom SARS-CoV-2 either caused or contributed to hospitalization, excluding those admitted with "incidental" infection.

View Article and Find Full Text PDF

The TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis) statement was published in 2015 to provide the minimum reporting recommendations for studies developing or evaluating the performance of a prediction model. Methodological advances in the field of prediction have since included the widespread use of artificial intelligence (AI) powered by machine learning methods to develop prediction models. An update to the TRIPOD statement is thus needed.

View Article and Find Full Text PDF

Aims/hypothesis: A precision medicine approach in type 2 diabetes could enhance targeting specific glucose-lowering therapies to individual patients most likely to benefit. We aimed to use the recently developed Bayesian causal forest (BCF) method to develop and validate an individualised treatment selection algorithm for two major type 2 diabetes drug classes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA).

Methods: We designed a predictive algorithm using BCF to estimate individual-level conditional average treatment effects for 12-month glycaemic outcome (HbA) between SGLT2i and GLP1-RA, based on routine clinical features of 46,394 people with type 2 diabetes in primary care in England (Clinical Practice Research Datalink; 27,319 for model development, 19,075 for hold-out validation), with additional external validation in 2252 people with type 2 diabetes from Scotland (SCI-Diabetes [Tayside & Fife]).

View Article and Find Full Text PDF

Objective: This study aimed to compare clinical and sociodemographic risk factors for severe COVID-19, influenza and pneumonia, in people with diabetes.

Design: Population-based cohort study.

Setting: UK primary care records (Clinical Practice Research Datalink) linked to mortality and hospital records.

View Article and Find Full Text PDF

Artificial intelligence as a medical device is increasingly being applied to healthcare for diagnosis, risk stratification and resource allocation. However, a growing body of evidence has highlighted the risk of algorithmic bias, which may perpetuate existing health inequity. This problem arises in part because of systemic inequalities in dataset curation, unequal opportunity to participate in research and inequalities of access.

View Article and Find Full Text PDF

 This article is one of a series aiming to inform analytical methods to improve comparability of estimates of ethnic health disparities based on different sources. This article explores the quality of ethnicity data and identifies potential sources of bias when ethnicity information is collected in three key NHS data sources. Future research can build on these findings to explore analytical methods to mitigate biases.

View Article and Find Full Text PDF

We outline essential considerations for any study of partial randomisation of research funding, and consider scenarios in which randomised controlled trials (RCTs) would be feasible and appropriate. We highlight the interdependence of target outcomes, sample availability and statistical power for determining the cost and feasibility of a trial. For many choices of target outcome, RCTs may be less practical and more expensive than they at first appear (in large part due to issues pertaining to sample size and statistical power).

View Article and Find Full Text PDF

Objective: To describe hospital admissions associated with SARS-CoV-2 infection in children and adolescents.

Design: Cohort study of 3.2 million first ascertained SARS-CoV-2 infections using electronic health care record data.

View Article and Find Full Text PDF

Objective: Precision medicine requires reliable identification of variation in patient-level outcomes with different available treatments, often termed treatment effect heterogeneity. We aimed to evaluate the comparative utility of individualized treatment selection strategies based on predicted individual-level treatment effects from a causal forest machine learning algorithm and a penalized regression model.

Methods: Cohort study characterizing individual-level glucose-lowering response (6 month reduction in HbA1c) in people with type 2 diabetes initiating SGLT2-inhibitor or DPP4-inhibitor therapy.

View Article and Find Full Text PDF

Climate-sensitive infectious disease modelling is crucial for public health planning and is underpinned by a complex network of software tools. We identified only 37 tools that incorporated both climate inputs and epidemiological information to produce an output of disease risk in one package, were transparently described and validated, were named (for future searching and versioning), and were accessible (ie, the code was published during the past 10 years or was available on a repository, web platform, or other user interface). We noted disproportionate representation of developers based at North American and European institutions.

View Article and Find Full Text PDF

Vaccination rates against SARS-CoV-2 in children aged five to eleven years remain low in many countries. The current benefit of vaccination in this age group has been questioned given that the large majority of children have now experienced at least one SARS-CoV-2 infection. However, protection from infection, vaccination or both wanes over time.

View Article and Find Full Text PDF

Background: Current treatment guidelines do not provide recommendations to support the selection of treatment for most people with type 2 diabetes. We aimed to develop and validate an algorithm to allow selection of optimal treatment based on glycaemic response, weight change, and tolerability outcomes when choosing between SGLT2 inhibitor or DPP-4 inhibitor therapies.

Methods: In this retrospective cohort study, we identified patients initiating SGLT2 and DPP-4 inhibitor therapies after Jan 1, 2013, from the UK Clinical Practice Research Datalink (CPRD).

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to define and validate ten COVID-19 phenotypes using linked electronic health records from the NHS in England, to better understand disease trajectories and support pandemic mitigation efforts.
  • The cohort included over 57 million individuals, identifying nearly 14 million COVID-19 events, with key findings showing a 12.7% infection rate, hospital admissions (6.4%), and varying mortality rates across different pandemic waves and treatment modalities.
  • Significant variances were observed in patient outcomes, such as higher mortality rates in wave 1 compared to wave 2 for non-ventilated hospital patients, with mortality being notably high for those receiving ventilatory support outside of ICU settings.
View Article and Find Full Text PDF

Objectives: To determine the psychometric validity, using Rasch analysis, of summing the three constituent parts of the Glasgow Coma Scale (GCS).

Design: National (registry-based) retrospective study.

Setting: England and Wales.

View Article and Find Full Text PDF

A growing number of artificial intelligence (AI)-based clinical decision support systems are showing promising performance in preclinical, in silico evaluation, but few have yet demonstrated real benefit to patient care. Early-stage clinical evaluation is important to assess an AI system's actual clinical performance at small scale, ensure its safety, evaluate the human factors surrounding its use and pave the way to further large-scale trials. However, the reporting of these early studies remains inadequate.

View Article and Find Full Text PDF

A growing number of artificial intelligence (AI)-based clinical decision support systems are showing promising performance in preclinical, in silico, evaluation, but few have yet demonstrated real benefit to patient care. Early stage clinical evaluation is important to assess an AI system’s actual clinical performance at small scale, ensure its safety, evaluate the human factors surrounding its use, and pave the way to further large scale trials. However, the reporting of these early studies remains inadequate.

View Article and Find Full Text PDF

Background: Beneficial response to first-line immunosuppressive azathioprine in patients with inflammatory bowel disease (IBD) is low due to high rates of adverse events. Co-administrating allopurinol has been shown to improve tolerability. However, data on this co-therapy as first-line treatment are scarce.

View Article and Find Full Text PDF